Paul-Ehrlich-Institut

Information on the Use of Cookies

In order to operate and optimise our website, we would like to collect and analyse statistical information completely anonymously. Will you accept the temporary use of statistics cookies?

You can revoke your consent at any time in our privacy policy.

OK

Coronavirus and COVID-19

COVID-19 Vaccines

COVID-19 vaccines in the EU/EEA (As of 1 December 2023, Source: Paul-Ehrlich-Institut)

Overview of authorised Vaccines

Short Overview COVID-19 Vaccine Products

In coordination with the pharmaceutical companies, the Paul-Ehrlich-Institut has prepared a short overview, which presents the most important characteristics of the different centrally procured vaccine products with regard to the presentation of the available multi-dose containers, dosage, and storage in a compact and clear format.

Bimervax

Bimervax (COVID-19 Vaccine HIPRA) is a protein-based vaccine (recombinant, adjuvanted) to protect against infections with the SARS-CoV-2 virus. It has been authorised in the EU since 30 March 2023. The authorisation holder is HIPRA Human Health, S.L.U., Spain.

Product Information

Product Information: Bimervax
European Public Assessment Report: Bimervax
Information sheet and anamnesis and consent sheet for the COVID-19 vaccination

Chronology

Comirnaty

Comirnaty is a mRNA vaccine to protect against infections with the SARS-CoV-2 virus. It has been authorised in the EU since 21 December 2020. The authorisation holder is BioNTech Manufacturing GmbH.

The following type II variations of Comirnaty vaccines adapted to the Omicron virus variant have been approved in the EU:

  • Comirnaty Original/Omicron BA.1
  • Comirnaty Original/Omicron BA.4-5
  • Comirnaty Omicron XBB.1.5

Product Information

Product Information: Comirnaty
European Public Assessment Report: Comirnaty
Information sheet and anamnesis and consent sheet for the COVID-19 vaccination

Chronology

Spikevax - COVID-19 Vaccine Moderna

Spikevax (COVID-19 Vaccine Moderna) is a mRNA vaccine to protect against infections with the SARS-CoV-2 virus. It has been authorised in the EU since 6 January 2021. The authorisation holder is Moderna Biotech Spain, S.L..

The following type II variations of Spikevax vaccines adapted to the Omicron virus variant have been approved in the EU:

  • Spikevax bivalent original/Omicron BA.1
  • Spikevax bivalent Original/Omicron BA.4-5
  • Spikevax XBB.1.5

Product Information

Product Information: Spikevax (COVID-19 Vaccine Moderna)
European Public Assessment Report: Spikevax (COVID-19 Vaccine Moderna)
Information sheet and anamnesis and consent sheet for the COVID-19 vaccination

Chronology

Jcovden - COVID-19 Vaccine Janssen

Jcovden (COVID-19 Vaccine Janssen) is a vector vaccine to protect against infections with the SARS-CoV-2 virus. It has been authorised in the EU since 11 March 2021. The authorisation holder is Janssen-Cilag International NV.

Product Informaton

Product Information: Jcovden (COVID-19 Vaccine Janssen)
Jcovden (COVID-19 Vaccine Janssen) European Public Assessment Report
Information sheet and anamnesis and consent sheet for the COVID-19 vaccination

Chronology

Vaxzevria - COVID-19 Vaccine AstraZeneca

Vaxzevria is a vector vaccine to protect against infections with the SARS-CoV-2 virus. It has been authorised in the EU since 29 January 2021. The authorisation holder is AstraZeneca AB, Sweden.

Product Information

Product Information: Vaxzevria (COVID-19 Vaccine AstraZeneca)
EPAR: Vaxzevria (COVID-19 Vaccine AstraZeneca)
Information sheet and anamnesis and consent sheet for the COVID-19 vaccination

Chronology

Nuvaxovid

Nuvaxovid (NVX-CoV2373) is a protein-based vaccine to protect against infections with the SARS-CoV-2 virus. It has been authorised in the EU since 20 December 2021. The authorisation holder is Novavax CZ a.s..

The following type II variation of the Nuvaxovid vaccine adapted to the Omicron virus variant has been approved in the EU:

  • Nuvaxovid XBB.1.5

Product Information

Product Information Nuvaxovid
European Public Assessment Report: Nuvaxovid
Information sheet and anamnesis and consent sheet for the COVID-19 vaccination

Chronology

VidPrevtyn Beta

Updates of the STIKO vaccination recommendations (German Only)

Vaccines in Development or Authorisation

WHO - Draft Landscape of COVID-19 Candidate Vaccines
EMA - COVID-19 Vaccines: under Evaluation
Authorised COVID-19 Vaccines

Content

  1. Role of the Paul-Ehrlich-Institut
  2. COVID-19 Vaccines
  3. Proof of vaccination within the meaning of the Infection Protection Act (IfSG)
  4. FAQ Coronavirus
  5. Safety of COVID-19 Vaccines
  6. Research Work
  7. SARS-CoV-2 Test Systems